{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:02:21Z","timestamp":1766066541855},"reference-count":14,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.mayocp.2015.07.019","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T15:33:53Z","timestamp":1441467233000},"page":"1424-1427","source":"Crossref","is-referenced-by-count":10,"title":["Fingolimod-Associated Peripheral Vascular Adverse Effects"],"prefix":"10.1016","volume":"90","author":[{"given":"Margherita","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Mazzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Placido","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco Salvatore","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocp.2015.07.019_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2015.07.019_bib2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","article-title":"Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.mayocp.2015.07.019_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/13543776.2013.783022","article-title":"Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012)","volume":"23","author":"Roberts","year":"2013","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"10.1016\/j.mayocp.2015.07.019_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","article-title":"Fingolimod-associated macular edema: incidence, detection and management","volume":"78","author":"Jain","year":"2012","journal-title":"Neurology"},{"issue":"1-3","key":"10.1016\/j.mayocp.2015.07.019_bib5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1388-1981(02)00173-7","article-title":"Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate","volume":"1582","author":"Siess","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.019_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2174\/138161206775474404","article-title":"Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases","volume":"12","author":"Yatomi","year":"2006","journal-title":"Curr Pharm Dis"},{"issue":"9","key":"10.1016\/j.mayocp.2015.07.019_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbalip.2008.04.003","article-title":"Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system","volume":"1781","author":"Takuwa","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mayocp.2015.07.019_bib8","first-page":"555","article-title":"Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis","volume":"8","author":"di Nuzzo","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2015.07.019_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1242\/dev.094805","article-title":"Sphingosine 1-phosphate signalling","volume":"141","author":"Mendelson","year":"2014","journal-title":"Development"},{"issue":"11","key":"10.1016\/j.mayocp.2015.07.019_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.mayocp.2015.07.019_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"Camm","year":"2014","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.mayocp.2015.07.019_bib12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1177\/1352458514525872","volume":"20","author":"Masera","year":"2014","journal-title":"Mult Scler"},{"issue":"24","key":"10.1016\/j.mayocp.2015.07.019_bib13","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1212\/WNL.0b013e3181e3972b","article-title":"Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis","volume":"74","author":"Schwarz","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mayocp.2015.07.019_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615006011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615006011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T17:53:39Z","timestamp":1537379619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615006011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0025619615006011"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.07.019","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}